Cellular Senescence Therapeutic Targeting

year: 2019
pmid: '30659283'

demaria2014: authors: Demaria M, et al title: An essential role for senescent cells in optimal wound healing journal: Dev Cell year: 2014 pmid: ‘25481258’ baker2018: authors: Baker DJ, Petersen RC title: Cellular senescence in brain aging and neurodegenerative diseases journal: Lancet Neurol year: 2018 pmid: ‘29371448’ copp2008: authors: Coppé JP, et al title: Senescence-associated secretory phenotypes reveal cell-nonautonomous functions journal: PLoS Biol year: 2008 pmid: ‘19177017’ blagosklonny2013: authors: Blagosklonny MV title: Rapamycin treatment of human cells journal: Cell Cycle year: 2013 pmid: ‘24217340’ herranz2015: authors: Herranz N, et al title: mTOR regulates MAPKAP-K2 activity to regulate the cellular senescence-associated secretory phenotype journal: Nat Cell Biol year: 2015 pmid: ‘26051178’ justice2024: authors: Justice JN, Nambiar AM, Tchkonia T, et al title: ‘Senolytics: pharmacological interventions for aging’ journal: J Gerontol A Biol Sci Med Sci year: 2024 hickson2023: authors: Hickson LJ, Langhi Prata LGP, Bobart SA, et al title: ‘Senolytics decrease senescent cells in humans: a pilot study’ journal: Aging Cell year: 2023 chaib2022: authors: Chaib S, Tchkonia T, Kirkland JL title: ‘Cellular senescence and senolytics: the path to translating age-related interventions’ journal: Nat Rev Drug Discov year: 2022

Cellular Senescence Therapeutic Targeting

Path: /mechanisms/senescence-therapeutic-targeting

Overview

Cellular senescence represents a fundamental aging mechanism that contributes to neurodegeneration through both cell-intrinsic dysfunction and the senescence-associated secretory phenotype (SASP)[@kirkland2018]. As senescent cells accumulate in the aging brain, they create a chronic pro-inflammatory microenvironment that drives pathology in Alzheimer’s disease, Parkinson’s disease, and related disorders[@baker2018]. Therapeutic targeting of senescence offers two complementary strategies: senolytic drugs that eliminate senescent cells, and senomorphic agents that suppress the harmful SASP without cell death[@he2017].

This page provides a comprehensive overview of therapeutic approaches to target cellular senescence in neurodegenerative diseases, including mechanistic details, clinical trial status, and intervention points for drug development.

Senolytic Drug Mechanisms

Senolytic drugs selectively induce apoptosis in senescent cells while sparing normal cells. The selective toxicity derives from the heightened dependence of senescent cells on anti-apoptotic pathways—particularly the Bcl-2 family proteins—to survive their pro-inflammatory state[@xu2018].

Dasatinib plus Quercetin (D+Q)

The combination of dasatinib (a tyrosine kinase inhibitor) and quercetin (a flavonoid) represents the most extensively studied senolytic regimen[@kirkland2018]. This combination was identified through high-throughput screening and demonstrated broad senolytic activity across multiple tissue types[@zhu2016].

Dasatinib is an FDA-approved drug for chronic myeloid leukemia that inhibits multiple kinases including Bcr-Abl and Src family kinases. In senescent cells, dasatinib targets Bcl-2, Bcl-xL, and Bcl-w survival proteins, shifting the balance toward apoptosis[@xu2018].

Quercetin is a natural flavonoid with multiple senolytic mechanisms including PI3K/Akt inhibition, Bcl-2 family modulation, and direct effects on multiple pro-survival pathways[@chaib2022]. The combination achieves synergistic senolytic activity with lower doses of each compound than would be required alone.

The D+Q combination has demonstrated preclinical efficacy in neurodegenerative disease models. In tauopathy mice, senolytic treatment reduced senescent glial cells and prevented tau-dependent pathology progression[@bussian2018]. In Alzheimer’s disease models, D+Q reduced cognitive decline and neuroinflammation through clearance of senescent microglia[@musi2018].

Navitoclax (ABT-263)

Navitoclax is a Bcl-2 family inhibitor that targets Bcl-2, Bcl-xL, and Bcl-w[@zhu2016]. Originally developed as an anti-cancer agent, navitoclax demonstrated potent senolytic activity particularly against senescent fibroblasts and astrocytes.

The mechanism involves:

1. Direct inhibition of anti-apoptotic Bcl-2 proteins
2. Activation of Bax/Bak-mediated mitochondrial apoptosis
3. Selective toxicity in senescent cells due to elevated anti-apoptotic protein expression

Navitoclax has shown particular efficacy against senescent microglia and neurons in vitro, making it relevant for neurodegenerative applications[@trias2019].

Other Senolytic Candidates

Senomorphic Approaches (SASP Suppression)

Senomorphic drugs do not eliminate senescent cells but instead suppress the production and secretion of SASP factors[@he2017]. This approach may offer advantages when complete senescent cell removal could have unintended consequences, such as impairing wound healing or tissue repair[@demaria2014].

Rapamycin and mTOR Inhibition

The mechanistic target of rapamycin (mTOR) pathway serves as a central regulator of SASP production[@laberge2015]. Rapamycin inhibits mTORC1, which:

• Reduces NF-κB activity through the kinase complex ILK[@herranz2015]
• Decreases translation of SASP mRNAs via 4E-BP1 phosphorylation
• Suppresses NLRP3 inflammasome activation and IL-1β production[@wang2019]

Rapamycin maintains the senescent cell growth arrest while rendering cells metabolically “quiet” with reduced SASP secretion[@blagosklonny2013]. This dual action—SASP suppression plus autophagy induction—makes rapamycin particularly potent.

Metformin

Metformin, the widely prescribed type 2 diabetes medication, exhibits senostatic properties through AMPK activation and subsequent mTOR inhibition[@moiseeva2013]. Metformin:

• Activates AMPK, which inhibits mTOR and reduces SASP
• Alters cellular metabolism to reduce pro-inflammatory signaling
• Modulates mitochondrial function in senescent cells

Large observational studies suggest reduced dementia risk in diabetic patients treated with metformin, and clinical trials are evaluating metformin’s neuroprotective effects in non-diabetic patients.

JAK-STAT Inhibition

The JAK-STAT pathway plays a critical role in SASP maintenance and autocrine signaling[@xu2015]. JAK inhibitors including ruxolitinib and tofacitinib:

• Block cytokine signaling required for SASP maintenance
• Reduce production of pro-inflammatory interleukins (IL-6, IL-8)
• Attenuate interferon-responsive gene expression

In preclinical models, JAK inhibition reduced SASP-induced cognitive decline and neuroinflammation.

SASP Modulation Strategies

Beyond direct senolytic and senomorphic approaches, additional strategies target specific aspects of SASP biology:

NF-κB Pathway Inhibition

Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) serves as the master regulator of SASP transcription. Inhibitors targeting this pathway include:

• BAY 11-7082: Direct IKK inhibitor
• Pyrrolidine dithiocarbamate: NF-κB DNA binding inhibitor
• Parthenolide: IKK and NF-κB targeting

p38 MAPK Inhibition

p38 mitogen-activated protein kinase contributes to SASP regulation through transcription factor C/EBPβ phosphorylation and SASP mRNA stabilization:

• SB203580: Selective p38α inhibitor
• SB239063: Brain-penetrant p38 inhibitor

IL-1β and NLRP3 Targeting

The NLRP3 inflammasome represents a key SASP-related target:

• MCC950: Potent NLRP3 inhibitor
• Canakinumab: Anti-IL-1β antibody (tested in Alzheimer’s disease)

Clinical Trial Landscape

Active Senolytic Trials in Neurodegeneration

Completed Trials and Findings

The first human senolytic trial (NCT02848131) in idiopathic pulmonary fibrosis demonstrated reduced senescent cell burden in peripheral blood with D+Q treatment[@hickson2023]. A Phase I trial in Alzheimer’s disease (NCT03415087) established safety and showed biomarker signals consistent with reduced senescence burden.

Challenges and Opportunities

Key challenges for clinical translation include:

1. Biomarker development: Validating circulating SASP factors (IL-6, IL-8, PAI-1) as treatment response markers
2. Patient selection: Identifying individuals with high senescent cell burden most likely to benefit
3. Dosing optimization: Intermittent versus continuous protocols remain under investigation
4. CNS penetration: Ensuring adequate drug concentrations in the brain

Biomarkers for Senescent Cell Burden

Circulating SASP Factors

The senescence-associated secretory phenotype (SASP) includes numerous secreted factors that can serve as biomarkers[@copp2008]:

Senescence Detection Methods

SA-β-Gal staining: Classic histochemical marker; limited to tissue samples

p16 and p21 markers:

• p16INK4a: Cell cycle inhibitor, increasingly used
• p21: Cyclin-dependent kinase inhibitor

DNA damage markers:

• γH2AX foci: DNA damage response
• 53BP1: DNA repair foci

Emerging approaches:

• Single-cell RNA sequencing
• Senescence-associated secretory phenotype profiling
• Machine learning on blood profiles

Disease-Specific Considerations

Alzheimer’s Disease

Cellular senescence in AD primarily affects[@ogrodnik2021]:

• Microglia: Senescent microglia accumulate with age and in AD brains, showing increased SASP and reduced phagocytic capacity
• Astrocytes: Senescent astrocytes produce pro-inflammatory cytokines that drive neuroinflammation
• Neurons: Some evidence of neuronal senescence in AD, though controversial

Therapeutic approach: Senolytic clearance of senescent glia followed by senomorphic treatment to prevent re-accumulation

Parkinson’s Disease

Senescence in PD involves:

• Dopaminergic neurons: Show markers of senescence in substantia nigra
• Microglia: Chronic senescence in PD brain
• Astrocytes: Contribute to neuroinflammation through SASP

Special considerations: The substantia nigra has high baseline oxidative stress, making combination approaches (antioxidants + senolytics) attractive

ALS

In ALS, senescence affects:

• Motor neurons: Show evidence of senescence
• Glia: Senescent astrocytes and microglia contribute to toxicity
• Muscle: Early senescence in muscle tissue

Frontotemporal Dementia

FTD shows senescence in:

• Neurons: TDP-43 pathology linked to senescence
• Glia: Region-specific patterns

Emerging Therapeutic Targets

Senolytic Pipeline

Senomorphic Pipeline

Novel Approaches

Senolytic antibodies: Targeting senescent cell surface antigens (uPAR, CD9) for antibody-dependent cellular cytotoxicity

Galactoside-based prodrugs: Activated specifically in senescent cells by elevated β-galactosidase

Gene therapy: Targeted expression of pro-apoptotic genes in senescent cells

Combination Strategies

Senolytic-Senomorphic Combinations

Combining senolytic and senostatic approaches may provide synergistic benefits[@kirkland2018]:

• D+Q + Rapamycin: Senolytic clearance plus SASP suppression
• Navitoclax + JAK inhibitors: Dual targeting of senescent cell survival and SASP
• Fisetin + Metformin: Natural senolytic with senostatic effects

Multi-Target Approaches

Targeting multiple hallmarks of aging:

• Senescence + proteostasis (rapamycin)
• Senescence + mitochondrial dysfunction (CoQ10)
• Senescence + neuroinflammation (MCC950)

Rationale: Neurodegeneration involves multiple interconnected pathways; monotherapy may be insufficient

Safety Considerations

Potential Risks

Off-target effects: Senolytic drugs may affect non-senescent cells, particularly during repeated dosing

Wound healing impairment: Senescent cells play important roles in tissue repair[@demaria2014]

Immune modulation: Chronic senolytic treatment may affect immune surveillance

Thrombocytopenia: Bcl-2 family inhibitors can cause platelet depletion

Monitoring Strategies

• Baseline and serial SASP biomarker measurement
• Platelet counts during Bcl-2 inhibitor treatment
• Cognitive and functional assessments
• Neuroimaging for brain penetration markers

Future Directions

Research Priorities

1. Biomarker validation: Establish validated biomarkers for senescent cell burden in humans
2. Delivery optimization: Develop brain-penetrant senolytic formulations
3. Combination trials: Test senolytic-senomorphic combinations in neurodegenerative diseases
4. Personalized approaches: Identify patient subgroups most likely to benefit

Emerging Areas

• Senescence vaccines: Active immunization against senescent cells
• Synthetic lethality: Exploiting senescent cell vulnerabilities
• Epigenetic therapies: Modulating senescence gene expression

Related Pages

flowchart TD
    A["Cellular Stress\nDNA damage, telomere erosion, oncogene activation"] --> B["Senescence Induction\nCell cycle arrest, SA-beta-gal positivity"]

    B --> C["SASP Production\nPro-inflammatory cytokines, chemokines, growth factors"]

    C --> D["Neuroinflammation\nMicroglial activation, astrocyte reactivity"]

    D --> E["Neuronal Dysfunction\nSynaptic loss, neurotransmitter imbalance"]

    E --> F["Neurodegeneration\nCognitive decline, motor symptoms"]

    G["SENOLYTICS"] -.->|"Eliminate senescent cells"| B

    G -->|"Induce apoptosis"| H["Bcl-2 family inhibitors\nDasatinib, Navitoclax"]
    H --> B

    I["SENOMORPHICS"] -.->|"Suppress SASP"| C

    I --> J["mTOR inhibitors\nRapamycin, Everolimus"]
    J -->|"Inhibit translation"| C

    I --> K["AMPK activators\nMetformin"]
    K -->|"Inhibit mTOR"| C

    I --> L["JAK inhibitors\nRuxolitinib, Tofacitinib"]
    L -->|"Block cytokine signaling"| C

    M["SASP Modulators"] -.->|"Target specific pathways"| C

    M --> N["NF-kappaB inhibitors\nBAY 11-7082"]
    M --> O["p38 MAPK inhibitors\nSB203580"]
    M --> P["NLRP3 inhibitors\nMCC950"]

    style B fill:#1a0a1f,stroke:#333
    style F fill:#3e2200,stroke:#333
    style G fill:#9f9,stroke:#333
    style I fill:#9f9,stroke:#333
    style M fill:#9f9,stroke:#333

Related Pages

• Senolytic Therapies for Neurodegenerative Diseases
• Senostatic Therapies for Neurodegeneration
• Cellular Senescence in Neurodegeneration
• SASP in Neurodegeneration
• Geroprotective Therapies for Neurodegeneration

Biomarkers for Senolytic Response

Clinical Biomarkers

Monbut invasive |

SASP as Treatment Response Marker

The senescence-associated secretory phenotype provides accessible biomarkers:

• IL-6: Highest correlation with senescent cell burden
• PAI-1: Plasminogen activator inhibitor-1, highly specific
• CXCL1: Pro-inflammatory chemokine
• VEGF: Angiogenic factor, elevated in senescence

Emerging Biomarkers

Single-cell approaches reveal cell-type-specific senescence signatures:

• snRNA-seq: Identifies senescent cell populations in brain tissue
• proteomics: Maps SASP protein composition
• epigenetic clocks: Biological aging indicators

Regulatory Considerations

FDA Pathway

Senolytics face unique regulatory challenges:

1. Indication selection: Aging-associated diseases vs. aging itself
2. Endpoint validation: Appropriate clinical outcomes
3. Combination therapy: Complexity of multi-drug regimens
4. Chronic vs. acute: Long-term treatment implications

Current Regulatory Status

Repurposing existing drugs for senolytic indications offers faster development paths.

Research Priorities

Preclinical

1. Model systems: Better in vitro and animal models of brain senescence
2. Target validation: Confirm senescent cell clearance improves function
3. Delivery: Brain-penetrant formulations
4. Combination: Rational combinations for synergistic effects

Clinical

1. Biomarker validation: Standardize SASP measurements
2. Patient selection: Identify high-burden populations
3. Dosing optimization: Intermittent vs. continuous protocols
4. Long-term safety: Extended monitoring for effects

Future Directions

Novel Modalities

• Senolytic antibodies: Targeted clearance via surface antigens
• Gene therapy: Inducible apoptosis in senescent cells
• Vaccination: Active immunization against senescent cells
• Nanoparticles: Targeted drug delivery

Combination Approaches

Future therapies will likely combine:

1. Senolytic clearance with senomorphic maintenance
2. Neuroinflammation modulation with tau/α-synuclein targeting
3. Metabolic support with cellular energetics enhancement

Precision Medicine

Understanding cell-type-specific senescenalth and disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28593998/) 6. van Deursen, The role of senescent cells in ageing (2014) 7. Zhu et al., Senolytic combinations for maximum effect (2016) 8. Laberge et al., MTOR regulates the pro-tumorigenic SASP (2015) 9. Moiseeva et al., Metformin suppresses the SASP (2013) 10. Xu et al., JAK inhibition alleviates the SASP (2015) 11. Trias et al., Senolytics eliminate senescent glia (2019) 12. Hickson et al., Senolytics decrease senescent cells in humans (2023) 13. Chaib et al., Cellular senescence and senolytics: the path to translating age-related interventions (2022) 14. Seluanov et al., Cellular senescence and the SASP in age-related diseases (2021) 15. Ogrodnik et al., Cellular senescence drives age-related dysfunction in neurodegenerative diseases (2021) 16. Justice et al., Senolytics: pharmacological interventions for aging (2024) 17. Demaria et al., An essential role for senescent cells in optimal wound healing (2014) 18. Baker & Petersen, Cellular senescence in brain aging and neurodegenerative diseases (2018) 19. Coppé et al., Senescence-associated secretory phenotypes reveal cell-nonautonomous functions (2008) 20. Blagosklonny, Rapamycin treatment of human cells (2013)

Pathway Diagram

The following diagram shows the key molecular relationships involving Cellular Senescence Therapeutic Targeting discovered through SciDEX knowledge graph analysis:

graph TD
    NFKB["NFKB"] -->|"regulates"| SASP["SASP"]
    senescence["senescence"] -->|"causes"| SASP["SASP"]
    NF__B["NF-κB"] -->|"activates"| SASP["SASP"]
    Senescent_Microglia["Senescent Microglia"] -->|"associated with"| SASP["SASP"]
    NFKB1["NFKB1"] -->|"promotes"| SASP["SASP"]
    NFKB["NFKB"] -->|"activates"| SASP["SASP"]
    senescent_cells["senescent cells"] -->|"develops"| SASP["SASP"]
    Senescent_Microglia["Senescent Microglia"] -->|"expressed in"| SASP["SASP"]
    senomorphics["senomorphics"] -.->|"inhibits"| SASP["SASP"]
    SDA_2026_04_01_gap_013["SDA-2026-04-01-gap-013"] -->|"investigates"| SASP["SASP"]
    senescent_glial_cells["senescent glial cells"] -->|"mediates"| SASP["SASP"]
    senomorphics["senomorphics"] -.->|"suppresses"| SASP["SASP"]
    TGM2["TGM2"] -->|"drives"| SASP["SASP"]
    Cys_D["Cys-D"] -.->|"suppresses"| SASP["SASP"]
    NF__B["NF-κB"] -->|"promotes"| SASP["SASP"]
    style NFKB fill:#4fc3f7,stroke:#333,color:#000
    style SASP fill:#4fc3f7,stroke:#333,color:#000
    style senescence fill:#4fc3f7,stroke:#333,color:#000
    style NF__B fill:#81c784,stroke:#333,color:#000
    style Senescent_Microglia fill:#80deea,stroke:#333,color:#000
    style NFKB1 fill:#4fc3f7,stroke:#333,color:#000
    style senescent_cells fill:#80deea,stroke:#333,color:#000
    style senomorphics fill:#ff8a65,stroke:#333,color:#000
    style SDA_2026_04_01_gap_013 fill:#4fc3f7,stroke:#333,color:#000
    style senescent_glial_cells fill:#80deea,stroke:#333,color:#000
    style TGM2 fill:#ce93d8,stroke:#333,color:#000
    style Cys_D fill:#ff8a65,stroke:#333,color:#000